2.50
Hdl Handle:
http://hdl.handle.net/2436/15838
Title:
Acute aldosterone antagonism improves cardiac vagal control in humans.
Authors:
Fletcher, Janine; Buch, Ashesh N.; Routledge, Helen C.; Chowdhary, Saqib; Coote, John H.; Townend, Jonathan N.
Abstract:
OBJECTIVES: We have examined the acute effects (<45 min) of aldosterone antagonism on heart rate variability and baroreflex sensitivity, markers of cardiac vagal control, in 13 healthy subjects. BACKGROUND: Evidence for the beneficial effects of aldosterone antagonists comes from studies showing increased survival rates following their addition to standard heart failure therapy. Many mechanisms have been suggested for this action, including effects upon the autonomic nervous system. METHODS: Heart rate variability and baroreflex sensitivity were examined 30 min following the administration of potassium canrenoate (intravenous) (aldosterone antagonist) or saline (control). RESULTS: Active treatment reduced resting heart rate (-6 +/- 1 beats/min [mean +/- standard error mean]) compared to control (0 +/- 1 beat/min) (p < 0.001) and increased measures of high frequency (HF) heart rate variability. Root mean square of successive RR interval differences increased by 21 +/- 5 ms versus -6 +/- 5 ms control (p < 0.001); HF power increased by 1,369 +/- 674 ms(2)with aldosterone antagonism compared to -255 +/- 431 ms(2) following saline infusion (p < 0.01). Baroreflex sensitivity (alpha-HF) was increased after active treatment (+4 +/- 2 ms/mm Hg vs. 0 +/- 1 ms/mm Hg control [p < 0.05]). No changes in plasma potassium levels were observed. CONCLUSIONS: These results provide evidence that aldosterone antagonists acutely improve cardiac vagal control, irrespective of any diuretic effects, and may in part explain their beneficial effects in treatment of heart failure.
Citation:
Journal of the American College of Cardiology, 43(7): 1270-1275
Publisher:
Elsevier BV
Issue Date:
2004
URI:
http://hdl.handle.net/2436/15838
DOI:
10.1016/j.jacc.2003.10.058
PubMed ID:
15063441
Additional Links:
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T18-4C2HRM1-T&_user=1644469&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000054077&_version=1&_urlVersion=0&_userid=1644469&md5=4eda71e0e3f12f1fd2198b16a2be989a
Type:
Article
Language:
en
Description:
Metadata only
ISSN:
0735-1097
Appears in Collections:
Centre for Health and Social Care Improvement

Full metadata record

DC FieldValue Language
dc.contributor.authorFletcher, Janine-
dc.contributor.authorBuch, Ashesh N.-
dc.contributor.authorRoutledge, Helen C.-
dc.contributor.authorChowdhary, Saqib-
dc.contributor.authorCoote, John H.-
dc.contributor.authorTownend, Jonathan N.-
dc.date.accessioned2008-01-08T15:27:48Z-
dc.date.available2008-01-08T15:27:48Z-
dc.date.issued2004-
dc.identifier.citationJournal of the American College of Cardiology, 43(7): 1270-1275en
dc.identifier.issn0735-1097-
dc.identifier.pmid15063441-
dc.identifier.doi10.1016/j.jacc.2003.10.058-
dc.identifier.urihttp://hdl.handle.net/2436/15838-
dc.descriptionMetadata onlyen
dc.description.abstractOBJECTIVES: We have examined the acute effects (<45 min) of aldosterone antagonism on heart rate variability and baroreflex sensitivity, markers of cardiac vagal control, in 13 healthy subjects. BACKGROUND: Evidence for the beneficial effects of aldosterone antagonists comes from studies showing increased survival rates following their addition to standard heart failure therapy. Many mechanisms have been suggested for this action, including effects upon the autonomic nervous system. METHODS: Heart rate variability and baroreflex sensitivity were examined 30 min following the administration of potassium canrenoate (intravenous) (aldosterone antagonist) or saline (control). RESULTS: Active treatment reduced resting heart rate (-6 +/- 1 beats/min [mean +/- standard error mean]) compared to control (0 +/- 1 beat/min) (p < 0.001) and increased measures of high frequency (HF) heart rate variability. Root mean square of successive RR interval differences increased by 21 +/- 5 ms versus -6 +/- 5 ms control (p < 0.001); HF power increased by 1,369 +/- 674 ms(2)with aldosterone antagonism compared to -255 +/- 431 ms(2) following saline infusion (p < 0.01). Baroreflex sensitivity (alpha-HF) was increased after active treatment (+4 +/- 2 ms/mm Hg vs. 0 +/- 1 ms/mm Hg control [p < 0.05]). No changes in plasma potassium levels were observed. CONCLUSIONS: These results provide evidence that aldosterone antagonists acutely improve cardiac vagal control, irrespective of any diuretic effects, and may in part explain their beneficial effects in treatment of heart failure.en
dc.language.isoenen
dc.publisherElsevier BVen
dc.relation.urlhttp://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T18-4C2HRM1-T&_user=1644469&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000054077&_version=1&_urlVersion=0&_userid=1644469&md5=4eda71e0e3f12f1fd2198b16a2be989a-
dc.subjectAldosterone antagonismen
dc.subjectHeart rateen
dc.subjectBaroreflex sensitivityen
dc.titleAcute aldosterone antagonism improves cardiac vagal control in humans.en
dc.typeArticleen

Related articles on PubMed

All Items in WIRE are protected by copyright, with all rights reserved, unless otherwise indicated.